rin) can be another issue. Jakl et al. (7) did not show any data for adherence to the antiplatelet regimen. Third, the cut-off of HPR (and LPR) can be different according to the cohort characteristics (12) because its contribution toward thrombus formation may vary according to its level of interaction with other thrombogenic components (e.g., inflammation, coagulation activity, shear stress, and endothelial dysfunction). Compared with the western population, East Asian population has a higher level of HPR (and LPR) cutoffs among AMI patients (13, 14) : East Asians may have a low tendency toward developing thrombophilia and a higher risk of bleeding. Without performing the receiver operating characteristic curve analysis, Jakl et al. (7) evaluated the clinical impact of predefined HPR cutoff on ischemic events. Finally, only platelet reactivity cannot explain the whole spectrum of the occurrence of thrombotic events. Conditions predisposing to thrombus formation may include abnormal vessel wall (vulnerable plaque), abnormal blood flow, and abnormal blood constituents (vulnerable blood). Jakl et al. (7) did not suggest detailed data regarding the lesion characteristics, stent profile, and important biochemical measurements. Risk prediction models or scoring systems, including important clinical or laboratory variables, can be more reliable for predicting clinical events and consequently help in the early introduction of personalized therapy.
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